Provectus announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of neuroendocrine tumors (NET) metastatic to the liver (mNET) refractory to somatostatin analogs and peptide receptor radionuclide therapy (PRRT) (NCT02693067) was presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), held from March 10-11, 2022 in a hybrid setting in Barcelona, Spain and online. The oral presentation was made by the principal investigator of the clinical trial's single center at The Queen Elizabeth Hospital (TQEH) in Adelaide, Australia: Tim Price, MBBS, DHlthSc (Medicine), FRACP, Head of Clinical Oncology Research and Chair of the combined Hematology and Medical Oncology Unit at TQEH, and Clinical Professor in the Faculty of Medicine at the University of Adelaide. Highlights from the 2022 ENETS Presentation: Patient characteristics N = 12 patients: 50% male; median age of 66 years (range 47-79) Primary tumor sites: 7 small bowel (58%), 3 pancreas (25%), 1 caecal (8%), and 1 unknown (8%; likely pancreas) NET grades: 5 Grade 1 (42%) and 7 Grade 2 (58%) All patients were refractory to SSA (100%), and 11 received PRRT (92%) as part of their prior treatment All patients had symptomatic, progressive disease Baseline chromogranin A (CgA): median 1,585 µg/L (range 35-10,370) PV-10 treatment 4 patients (33%) received more than 1 dose (range 2-4) 8 patients (67%) received 1 dose.

Safety: All treatment-emergent adverse events (TEAEs) were Grade 1 or 2, primarily injection site pain (75%) Single subjects experienced Grade 3 TEAEs of photosensitivity reaction or transaminases increased. Efficacy Median progression-free survival (mPFS): 9.4 months (range 1.0-41.8) Median overall survival (mOS): 22.5 months (range 5.5-42.3); 4 patients alive Subgroup analysis of primary NET histology, pancreas vs intestine: mPFS 2.7 months vs 19.7 months; mOS 11.8 months vs 25.5 monthsQuality of life (QOL) Stable or improved health status and symptoms after 3 months in most patients.